Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.64 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | GRK2 | P25098 | 5/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.51 |
| ▸ | GRK5 | P34947 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | PRKCB | P05771 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | GRK6 | P43250 | 1/20 | 0.51 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.51 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.51 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19338476 | 0.86 | MMP13 (0.65) | MMP13SLC22A8GRK2ROCK1GRK5 | |
| SCHEMBL29147374 | 0.85 | MMP13 (0.64) | MMP13SLC22A8GRK2ROCK1GRK5 | |
| SCHEMBL2315834 | 0.85 | MMP13 (0.64) | MMP13SLC22A8GRK2ROCK1GRK5 | |
| SCHEMBL6302762 | 0.84 | MMP13 (0.65) | MMP13SLC22A8HDAC3HDAC4HDAC1 | |
| SCHEMBL6302269 | 0.84 | MMP13 (0.60) | MMP13GRK2GRK5HDAC3HDAC4 | |
| SCHEMBL6014176 | 0.83 | GRK2 (0.65) | MMP13GRK2GRK5GRK1 | |
| SCHEMBL5423323 | 0.82 | MMP13 (0.55) | MMP13SLC22A8GRK2ROCK1GRK5 | |
| SCHEMBL2494650 | 0.81 | MMP13 (0.68) | MMP13SLC22A8GRK2ROCK1GRK5 | |
| SCHEMBL2317224 | 0.81 | MMP13 (0.59) | MMP13SLC22A8KDM4E | |
| SCHEMBL6298035 | 0.81 | MMP13 (0.64) | MMP13SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| EP-1966214-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | MMP13 4308/4885SLC22A8 3671/4885GRK2 58/4885 |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | MMP13 4308/4885SLC22A8 3671/4885GRK2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.